# Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

> **NCT05872204** · PHASE2 · RECRUITING · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 100 (estimated)

## Conditions studied

- Low Grade Serous Ovarian Carcinoma
- Adult Type Granulosa Cell Tumor

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT05872204
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05872204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05872204, "Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT05872204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*